Jeffrey G. Leflein

Allergy and Immunology

2000 N Huron River Dr Ste 200
Ypsilanti, MI 48197

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

A Randomized Dose-Finding Study of Anti-KIT Barzolvolimab in Patients with Chronic Spontaneous Urticaria.

A Randomized Dose-Finding Study of Anti-KIT Barzolvolimab in Patients with Chronic Spontaneous Urticaria.

Journal: The Journal of allergy and clinical immunology

Published: October 01, 2025

Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy.

Efficacy and Safety of Ligelizumab in Individuals With Confirmed Peanut Allergy.

Journal: Allergy

Published: June 10, 2025

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.

Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study.

Journal: Allergy

Published: December 13, 2023

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.

Journal: Allergy

Published: December 13, 2023

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.

Journal: Lancet (London, England)

Published: January 24, 2023

Showing 1-5 of 5

Last Updated: 09/26/2026